vimarsana.com
Home
Live Updates
ADC Therapeutics Doses First Patient in Phase 1b Clinical Tr
ADC Therapeutics Doses First Patient in Phase 1b Clinical Tr
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
ADCT-601 binds to AXL, a cancer antigen expressed in solid tumors such as sarcoma and is associated with resistance to chemotherapy
ADCT-601 was observed to have a manageable tolerability profile as... | July 27, 2022
Related Keywords
Switzerland ,
New Jersey ,
United States ,
London ,
City Of ,
United Kingdom ,
Lausanne Biop ,
Joseph Camardo ,
Linkedin ,
Company On Twitter ,
Chief Medical Officer ,
San Francisco Bay Area ,
Adc Therapeutics Sa Stock Exchange ,
News ,
Information ,
Press Release ,
Kinds ,
O ,
Dancer ,
Ntigen ,
Xpressed ,
N ,
Olid ,
Rumors ,
Much ,
Us ,
Tarcoma ,
End ,
Ssociated ,
Ith ,
Resistance ,
Gas ,
Bserved ,
Wave ,
Unmanageable ,
Tolerability ,
Rofile Adct Ch0499880968 ,